Evox Therapeutics, an exosome therapeutics company, has announced the publication of its research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes.
This month saw BioCina officially open its new biologics manufacturing facility in Adelaide, Australia, flagging it as the only TGA, EMA, Health Canada and US-FDA approved commercial facility of its kind in the country.
Researchers at the European Molecular Biology Laboratory (EMBL) have identified sequences in human proteins that might be used by SARS-CoV-2 to infect cells.
LenioBio and Fraunhofer Institute IME have entered a licensing agreement, allowing LenioBio to commercialize technology into a protein expression platform.
Recent investments in antibody-drug conjugate (ADC) technology will translate into more products on the market, but it will take time says Polytherics who has extended its licensing deal with MacroGenics.
